surmount-1 tirzepatide obesity nejm 2022 weight loss percent for Treatment and Diabetes Prevention SURMOUNT-1 Tirzepatide Trial — 22.5%

The weight loss effects of tirzepatide are notable, as obesity is a major risk factor for the development of T2DM and cardiovascular diseases

Tirzepatide interactions The FDA notes that tirzepatide can interact with other drugs, so it's important to discuss all other medications you're taking with your provider

Not changing eating habits during treatment If tirzepatide was your entire weight management strategy, meaning you ate whatever you wanted just in smaller amounts because the medication killed your appetite, you have a problem

Many users do well at 10 mg without escalating further

Our goal is never to rush into treatment

Social-media users have also speculated that other boldfacers such as Kim Kardashian have been using the diabetes drugs to slim down